To systematically evaluate genetic, cell-intrinsic determinants of IFN-γ signaling, and nominate genes for further investigation, we performed CRISPR-Cas9 screens in two BRAF-mutant CRC cell lines, HT-29 (microsatellite stable) and LS-411N (microsatellite unstable [MSI]) (Figure 1A). The gene discussed is BRAF; the disease is colorectal carcinoma.